Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

Published:2008 Issue:3-4 Volume:74 Page:223-228
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Boccardo Francesco,Rubagotti Alessandra,Conti Giario,Battaglia Michele,Cruciani Giorgio,Manganelli Antonio,Ricci Sergio,Lapini Alberto

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression;Biomaterials Science;2024

2. Signaling Pathways That Control Apoptosis in Prostate Cancer;Cancers;2021-02-24

3. Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies;Clinical Genitourinary Cancer;2018-04

4. Gefitinib;Adverse Events and Oncotargeted Kinase Inhibitors;2017

5. An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China;PLOS ONE;2016-12-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP